1501-38-8

Basic information

• Product Name: 3-(3,4-Dihydro-4-methyl-3-oxoquinoxalin-2-yl)propionic acid, 3-(2-Carboxyethyl)-1,2-dihydro-1-methyl-2-oxoquinoxaline
• Synonyms: 3-(3,4-Dihydro-4-methyl-3-oxoquinoxalin-2-yl)propanoic acid;3-(3,4-Dihydro-4-methyl-3-oxoquinoxalin-2-yl)propionic acid, 3-(2-Carboxyethyl)-1,2-dihydro-1-methyl-2-oxoquinoxaline;3-(4-methyl-3-oxo-3,4-dihydroquinoxalin-2-yl)propanoic acid
• CAS NO: 1501-38-8
• Molecular Formula: C12H12N2O3
• Molecular Weight: 232.23528
• Mol File: 1501-38-8.mol
• Article Data: 2

Chemical Properties

• Melting Point: 180-182 °C
• Boiling Point: 447.9°Cat760mmHg
• Flash Point: 224.7°C
• Appearance: /
• Density: 1.32g/cm³
• Vapor Pressure: 8.3E-09mmHg at 25°C
• Refractive Index: 1.627
• PKA: 4.36±0.10(Predicted)
• CAS DataBase Reference: 3-(3,4-Dihydro-4-methyl-3-oxoquinoxalin-2-yl)propionic acid, 3-(2-Carboxyethyl)-1,2-dihydro-1-methyl-2-oxoquinoxaline(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(3,4-Dihydro-4-methyl-3-oxoquinoxalin-2-yl)propionic acid, 3-(2-Carboxyethyl)-1,2-dihydro-1-methyl-2-oxoquinoxaline(1501-38-8)
• EPA Substance Registry System: 3-(3,4-Dihydro-4-methyl-3-oxoquinoxalin-2-yl)propionic acid, 3-(2-Carboxyethyl)-1,2-dihydro-1-methyl-2-oxoquinoxaline(1501-38-8)

Safety Data

• Hazardous Substances Data: 1501-38-8(Hazardous Substances Data)

Usage

InChI:InChI=1/C12H12N2O3/c1-14-10-5-3-2-4-8(10)13-9(12(14)17)6-7-11(15)16/h2-5H,6-7H2,1H3,(H,15,16)

Upstream product

• 91807-20-4 3-(3-oxo-3,4-dihydroquinoxalin-2-yl)propionic acid ethyl ester 
• 5965-53-7 diethyl 2-ketoglutarate 
• 328-50-7 α-ketoglutaric acid 
• 91807-20-4 ethyl 3-(3-oxo-3,4-dihydroquinoxalin-2-yl)propanoate 

Relevant articles and documents

Small Molecule Antagonists of the Interaction between the Histone Deacetylase 6 Zinc-Finger Domain and Ubiquitin

Inhibitors of HDAC6 have attractive potential in numerous cancers. HDAC6 inhibitors to date target the catalytic domains, but targeting the unique zinc-finger ubiquitin-binding domain (Zf-UBD) of HDAC6 may be an attractive alternative strategy. We developed X-ray crystallography and biophysical assays to identify and characterize small molecules capable of binding to the Zf-UBD and competing with ubiquitin binding. Our results revealed two adjacent ligand-able pockets of HDAC6 Zf-UBD and the first functional ligands for this domain.